Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 13 | 2023 | 314 | 3.000 |
Why?
|
| Hepacivirus | 6 | 2020 | 140 | 2.900 |
Why?
|
| Hepatitis C, Chronic | 5 | 2018 | 88 | 2.020 |
Why?
|
| Physicians | 6 | 2023 | 437 | 1.550 |
Why?
|
| Hepatitis C | 2 | 2020 | 139 | 1.040 |
Why?
|
| Genotype | 6 | 2018 | 639 | 0.870 |
Why?
|
| Endocarditis | 1 | 2022 | 20 | 0.800 |
Why?
|
| Bacteremia | 1 | 2022 | 93 | 0.750 |
Why?
|
| Ribavirin | 4 | 2017 | 24 | 0.740 |
Why?
|
| Dibenzothiepins | 1 | 2020 | 1 | 0.730 |
Why?
|
| World Health Organization | 1 | 2020 | 30 | 0.720 |
Why?
|
| Medicine | 1 | 2021 | 56 | 0.710 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2020 | 3 | 0.700 |
Why?
|
| Communicable Diseases | 1 | 2021 | 83 | 0.700 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2020 | 23 | 0.690 |
Why?
|
| Adenosine Monophosphate | 5 | 2022 | 24 | 0.650 |
Why?
|
| Alanine | 5 | 2022 | 46 | 0.650 |
Why?
|
| Disease Management | 1 | 2020 | 220 | 0.620 |
Why?
|
| Sofosbuvir | 2 | 2017 | 18 | 0.600 |
Why?
|
| Influenza, Human | 1 | 2020 | 193 | 0.600 |
Why?
|
| Sustained Virologic Response | 1 | 2017 | 10 | 0.570 |
Why?
|
| Patient Safety | 1 | 2020 | 244 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 2 | 2022 | 705 | 0.560 |
Why?
|
| Motivation | 1 | 2019 | 266 | 0.550 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 168 | 0.550 |
Why?
|
| Tuberculosis | 1 | 2019 | 263 | 0.510 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 432 | 0.490 |
Why?
|
| Humans | 34 | 2024 | 59512 | 0.460 |
Why?
|
| Interferons | 1 | 2014 | 63 | 0.440 |
Why?
|
| Paranasal Sinuses | 1 | 2013 | 7 | 0.440 |
Why?
|
| Heroin | 1 | 2013 | 12 | 0.430 |
Why?
|
| Mouth | 1 | 2013 | 32 | 0.430 |
Why?
|
| Nose | 1 | 2013 | 27 | 0.430 |
Why?
|
| Pneumonia, Viral | 3 | 2021 | 199 | 0.430 |
Why?
|
| Cocaine | 1 | 2013 | 86 | 0.410 |
Why?
|
| Travel Medicine | 1 | 2011 | 3 | 0.380 |
Why?
|
| Proline | 3 | 2018 | 39 | 0.380 |
Why?
|
| Travel | 1 | 2011 | 31 | 0.370 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 38 | 0.370 |
Why?
|
| Ambulatory Care | 2 | 2024 | 300 | 0.370 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 19 | 0.350 |
Why?
|
| United States | 11 | 2024 | 7530 | 0.340 |
Why?
|
| Pharmacists | 1 | 2011 | 124 | 0.340 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 187 | 0.320 |
Why?
|
| Pandemics | 3 | 2024 | 610 | 0.290 |
Why?
|
| Ritonavir | 2 | 2023 | 14 | 0.260 |
Why?
|
| Chloroquine | 3 | 2020 | 48 | 0.250 |
Why?
|
| Viral Load | 2 | 2017 | 229 | 0.240 |
Why?
|
| Betacoronavirus | 3 | 2020 | 160 | 0.230 |
Why?
|
| Antibody Formation | 2 | 2022 | 111 | 0.230 |
Why?
|
| Azithromycin | 2 | 2020 | 26 | 0.220 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 303 | 0.200 |
Why?
|
| Certification | 1 | 2021 | 49 | 0.180 |
Why?
|
| Specialization | 1 | 2021 | 73 | 0.180 |
Why?
|
| Triazines | 1 | 2020 | 19 | 0.180 |
Why?
|
| Politics | 1 | 2020 | 31 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2329 | 0.180 |
Why?
|
| Pyridones | 1 | 2020 | 35 | 0.180 |
Why?
|
| Masks | 1 | 2020 | 20 | 0.170 |
Why?
|
| Morpholines | 1 | 2020 | 85 | 0.170 |
Why?
|
| Male | 8 | 2024 | 27582 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 20 | 0.170 |
Why?
|
| Counseling | 1 | 2022 | 352 | 0.170 |
Why?
|
| Organizational Culture | 1 | 2020 | 112 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 158 | 0.160 |
Why?
|
| Aged | 5 | 2024 | 13358 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 567 | 0.150 |
Why?
|
| Immunity, Innate | 2 | 2022 | 764 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2022 | 480 | 0.150 |
Why?
|
| Anilides | 1 | 2018 | 15 | 0.150 |
Why?
|
| Macrocyclic Compounds | 1 | 2018 | 8 | 0.150 |
Why?
|
| Valine | 1 | 2018 | 30 | 0.150 |
Why?
|
| Hepatitis B, Chronic | 1 | 2017 | 4 | 0.150 |
Why?
|
| Carbamates | 1 | 2018 | 25 | 0.150 |
Why?
|
| Hepatitis B Vaccines | 1 | 2017 | 13 | 0.150 |
Why?
|
| Machine Learning | 1 | 2019 | 140 | 0.150 |
Why?
|
| Lactams, Macrocyclic | 1 | 2018 | 25 | 0.150 |
Why?
|
| Cyclopropanes | 1 | 2018 | 41 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 670 | 0.140 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 6 | 0.140 |
Why?
|
| Fluorenes | 1 | 2017 | 13 | 0.140 |
Why?
|
| Hospitalization | 1 | 2024 | 1287 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2018 | 123 | 0.140 |
Why?
|
| Interferon-alpha | 2 | 2015 | 98 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6013 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2017 | 59 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1024 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 421 | 0.130 |
Why?
|
| Polyethylene Glycols | 2 | 2015 | 163 | 0.130 |
Why?
|
| Plasmodium falciparum | 1 | 2017 | 132 | 0.130 |
Why?
|
| Malaria, Falciparum | 1 | 2017 | 115 | 0.130 |
Why?
|
| Vaccination | 1 | 2017 | 335 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2015 | 693 | 0.120 |
Why?
|
| Retreatment | 1 | 2015 | 45 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 442 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2015 | 130 | 0.120 |
Why?
|
| Adult | 7 | 2023 | 15776 | 0.110 |
Why?
|
| Head Injuries, Penetrating | 1 | 2013 | 5 | 0.110 |
Why?
|
| Vietnam | 1 | 2014 | 160 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2014 | 188 | 0.110 |
Why?
|
| Skull | 1 | 2013 | 57 | 0.110 |
Why?
|
| Frontal Lobe | 1 | 2013 | 65 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 93 | 0.110 |
Why?
|
| Female | 6 | 2024 | 30914 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2014 | 344 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 98 | 0.100 |
Why?
|
| Mass Screening | 1 | 2017 | 649 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 279 | 0.090 |
Why?
|
| Mutation | 1 | 2018 | 2445 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2022 | 330 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 1463 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2015 | 5180 | 0.060 |
Why?
|
| Outpatients | 1 | 2023 | 132 | 0.050 |
Why?
|
| Pregnancy | 2 | 2017 | 2355 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2020 | 204 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 2443 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 454 | 0.040 |
Why?
|
| Middle Aged | 3 | 2024 | 16278 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 5014 | 0.040 |
Why?
|
| Quinidine | 1 | 2017 | 2 | 0.040 |
Why?
|
| Gravidity | 1 | 2017 | 12 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 38 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 60 | 0.030 |
Why?
|
| Antimalarials | 1 | 2017 | 68 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 541 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1454 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 577 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 410 | 0.030 |
Why?
|
| Accidents, Home | 1 | 2013 | 12 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1286 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 159 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 1090 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1226 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1516 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 1198 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 992 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4326 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 5922 | 0.010 |
Why?
|